Insuman Basal Solostar (Insulin Human (Rdna))

• Insuman Basal Solostar provides basal insulin therapy for the diabetes mellitus disease family.
• Type 1 diabetes mellitus: supplies long‑acting insulin to maintain fasting glucose levels and reduce hyperglycaemic episodes.
• Type 2 diabetes mellitus: adds basal insulin to complement oral agents when glycaemic control is insufficient.
• Gestational diabetes mellitus: may be prescribed when insulin therapy is required to achieve target glucose levels during pregnancy.

• Insulin Human binds to insulin receptors on muscle, adipose and hepatic cells, activating the receptor’s intrinsic tyrosine kinase activity. This triggers downstream signaling pathways that promote glucose uptake via GLUT‑4 translocation, enhance glycogen synthesis, inhibit gluconeogenesis, and suppress lipolysis. The result is a reduction in circulating blood glucose and improved metabolic utilization of glucose. It also facilitates protein synthesis and potassium entry into cells, contributing to overall anabolic effects.

Insuman Basal Solostar may be associated with the following adverse reactions.

Common Side Effects

• Hypoglycaemia: low blood glucose episodes, especially if meals are missed or dosage is excessive.
• Injection site reactions: redness, swelling, or itching at the administration site.
• Weight gain: gradual increase in body weight due to improved glucose utilization.
• Edema: mild peripheral fluid retention, often in the lower extremities.

Serious or Rare Side Effects

• Severe hypoglycaemia: profound low glucose leading to seizures, loss of consciousness, or coma.
• Allergic reactions: urticaria, angioedema, or anaphylaxis requiring immediate medical attention.
• Lipodystrophy: abnormal fat distribution at injection sites, potentially causing lipoatrophy or lipohypertrophy.
• Insulin antibody formation: rare immune response that may alter insulin efficacy.

When using Insuman Basal Solostar, consider the following precautions and warnings.

• Dose adjustment: modify the insulin dose in patients with renal or hepatic impairment to avoid hypoglycaemia.
• Blood glucose monitoring: perform frequent self‑monitoring of blood glucose, especially during therapy initiation or dose changes.
• Hypoglycaemia risk: do not administer if the patient is experiencing low blood glucose; treat promptly if it occurs.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk, as safety data are limited.
• Hypersensitivity: discontinue if signs of an allergic reaction such as rash, swelling, or breathing difficulty appear.
• Store at 2-8 °C: keep the product refrigerated, protect from light, and do not freeze or shake the vial.

Insuman Basal Solostar can interact with other medicines; relevant interactions are grouped below.

Major Interactions (Avoid)

• Sulfonylureas or meglitinides: combined use may cause severe hypoglycaemia; dose reduction or close monitoring is required.
• Beta‑blockers: may mask typical hypoglycaemia symptoms, making detection difficult.
• MAO‑inhibitors: can potentiate insulin’s glucose‑lowering effect, increasing hypoglycaemia risk.

Moderate Interactions (Monitor Closely)

• Thiazolidinediones: may increase insulin resistance, requiring possible dose adjustments.
• Corticosteroids: raise blood glucose levels, potentially necessitating higher insulin doses.
• ACE inhibitors or ARBs: can enhance insulin sensitivity, leading to modest hypoglycaemia risk.